FLT3 and acute myeloid leukemia: It was performed in 47% of our r/r/secondary AML patients and was estimated to be the only factor significantly influencing OS, among other variables, namely, FLT3 mutation, ELN adverse risk, FLAG vs. FLAG-Ida, and age.